Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.007
Neutral
RSI(14)
49.749
Neutral
STOCH(KDJ)(9,3,3)
39.104
Neutral
ATR(14)
0.129
High Vlolatility
CCI(14)
-74.160
Neutral
Williams %R
62.857
Sell
TRIX(12,20)
0.261
Sell
StochRSI(14)
53.842
Sell
Rein Therapeutics Inc
RNTX1.260USD
-0.010-0.80%
Market hours （ET）Quotes delayed by 15 min
926.67KMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Rein Therapeutics Inc
Currency: USD Updated: 2026-03-27Key Insights
Rein Therapeutics Inc's fundamentals are relatively weak, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 164 out of 391 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 10.00.In the medium term, the stock price is expected to trend up.Despite a good stock market performance and strong technicals over the past month, the fundamentals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Rein Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Rein Therapeutics Inc Highlights
StrengthsRisks
Rein Therapeutics, Inc., formerly Aileron Therapeutics, Inc., is a clinical-stage biopharmaceutical company advancing a novel pipeline of first-in-class therapies to address significant unmet medical needs in orphan pulmonary and fibrosis indications. The Company's lead product candidate, LTI-03 (idiopathic pulmonary fibrosis), is a novel, synthetic peptide with a dual mechanism targeting alveolar epithelial cell survival as well as inhibition of profibrotic signaling. Its second product candidate, LTI-01, is a proenzyme that has completed Phase 1b and Phase 2a clinical trials for the treatment of loculated pleural effusions. LTI-01 has received Orphan Drug Designation in the United States and European Union and Fast Track Designation in the United States. Its pipeline also includes LTI-05 (cystic fibrosis).
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 0.00.
Fairly Valued
The company’s latest PE is -0.64, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 8.73M shares, decreasing 14.38% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 22.70K shares of this stock.
Analyst Rating
Based on
2
analysts
Buy
Current Rating
10.000
Target Price
+687.40%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-03-27The current financial score of Rein Therapeutics Inc is 5.52, ranking 348 out of 391 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is low.
Score
Financials
2.04
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
7.77
Operational Efficiency
4.00
Growth Potential
6.75
Shareholder Returns
7.03
Rein Therapeutics Inc's Company Valuation
Currency: USD Updated: 2026-03-27The current valuation score of Rein Therapeutics Inc is 8.36, ranking 48 out of 391 in the Biotechnology & Medical Research industry. Its current P/E ratio is -0.64, which is -67.18% below the recent high of -0.21 and -217.65% above the recent low of -2.03.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 164/391
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-03-27The current earnings forecast score of Rein Therapeutics Inc is 7.00, ranking 312 out of 391 in the Biotechnology & Medical Research industry. The average price target is 8.00, with a high of 10.00 and a low of 6.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
2
analysts
Buy
Current Rating
10.000
Target Price
+687.40%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
548
Total
6
Median
6
Average
Company name
Ratings
Analysts
Rein Therapeutics Inc
RNTX
2
CRISPR Therapeutics AG
CRSP
29
IQVIA Holdings Inc
IQV
27
argenx SE
ARGX
26
Intellia Therapeutics Inc
NTLA
24
Beigene Ltd
ONC
24
1
2
3
...
110
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-03-27The current price momentum score of Rein Therapeutics Inc is 7.05, ranking 87 out of 391 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 1.44 and the support level at 1.09, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
1.246
Buy
MA10
1.289
Sell
MA20
1.256
Buy
MA50
1.247
Buy
MA100
1.308
Sell
MA200
1.320
Sell
Institutional Confidence
Currency: USD Updated: 2026-03-27The current institutional shareholding score of Rein Therapeutics Inc is 3.00, ranking 195 out of 391 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 33.21%, representing a quarter-over-quarter decrease of 3.41%. The largest institutional shareholder is The Vanguard, holding a total of 1.17M shares, representing 4.43% of shares outstanding, with 36.16% increase in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
Voss Capital LLC
Bios Equity Partners, LP.
University of Texas Investment Management Company
Prosight Capital
Cable Car Capital LLC
Geode Capital Management, L.L.C.
Texas Capital Bank Private Wealth Advisors
Sigma Planning Corporation
Gagnon Securities LLC
1
2
Risk Assessment
Currency: USD Updated: 2026-03-27The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. No risk assessment score is currently available for Rein Therapeutics Inc. The Biotechnology & Medical Research industry's average is 3.38. The company's beta value is 0.00. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.
Score
Beta vs S&P 500 index
--
VaR
+8.56%
240-Day Maximum Drawdown
+54.66%
240-Day Volatility
+111.88%
Return
Best Daily Return
60 days
+13.14%
120 days
+21.01%
5 years
+115.66%
Worst Daily Return
60 days
-9.09%
120 days
-18.86%
5 years
-37.77%
Sharpe Ratio
60 days
+0.88
120 days
+0.61
5 years
-0.08
Risk Assessment
Maximum Drawdown
240 days
+54.66%
3 years
+84.56%
5 years
+96.18%
Return-to-Drawdown Ratio
240 days
-0.49
3 years
-0.04
5 years
-0.20
Skewness
240 days
+0.82
3 years
+5.40
5 years
+4.18
Volatility
Realised Volatility
240 days
+111.88%
5 years
+118.54%
Standardised True Range
240 days
+10.81%
5 years
+34.38%
Downside Risk-Adjusted Return
120 days
+116.27%
240 days
+116.27%
Maximum Daily Upside Volatility
60 days
+64.47%
Maximum Daily Downside Volatility
60 days
+52.72%
Liquidity
Average Turnover Rate
60 days
+0.26%
120 days
+0.21%
5 years
--
Turnover Deviation
20 days
-44.39%
60 days
-63.55%
120 days
-69.85%
Peer Comparison
Biotechnology & Medical Research
Rein Therapeutics Inc
RNTX
5.74 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Alkermes Plc
ALKS
8.42 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Madrigal Pharmaceuticals Inc
MDGL
8.27 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
BioCryst Pharmaceuticals Inc
BCRX
8.27 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Day One Biopharmaceuticals Inc
DAWN
8.26 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
IQVIA Holdings Inc
IQV
8.21 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
